Literature DB >> 29381246

Evidence in support of hyperkalaemia management strategies: A systematic literature review.

Eirini Palaka1, Saoirse Leonard2, Amy Buchanan-Hughes2, Anna Bobrowska2, Bryony Langford2, Susan Grandy3.   

Abstract

BACKGROUND: Hyperkalaemia is a potentially life-threatening condition that can be managed with pharmacological and non-pharmacological approaches. With the recent development of new hyperkalaemia treatments, new information on safe and effective management of hyperkalaemia has emerged.
OBJECTIVES: This systematic literature review (SLR) aimed to identify all relevant comparative and non-comparative clinical data on management of hyperkalaemia in adults. Our secondary aim was to assess the feasibility of quantitatively comparing randomised controlled trial (RCT) data on the novel treatment sodium zirconium cyclosilicate (ZS) and established pharmacological treatments for the non-emergency management of hyperkalaemia, such as the cation-exchangers sodium/calcium polystyrene sulphonate (SPS/CPS).
METHODS: MEDLINE, Embase and the Cochrane Library were searched on 3rd April 2017, with additional hand-searches of key congresses and previous SLRs. Articles were screened by two independent reviewers. Eligible records reported interventional or observational studies of pharmacological or non-pharmacological management of hyperkalaemia in adults.
RESULTS: Database searches identified 2,073 unique records. Two hundred and one publications were included, reporting 30 RCTs, 29 interventional non-RCTs and 43 observational studies. Interventions investigated in RCTs included ZS (3), SPS/CPS (3), patiromer (4) and combinations of temporising agents (6 RCTs). A robust and meaningful indirect treatment comparison between ZS and long-established cation-binding agents (SPS/CPS) was infeasible because of heterogeneity between studies (including time points and dosing) and small sample size in SPS/CPS studies.
CONCLUSIONS: Despite hyperkalaemia being associated with several chronic diseases, there is a paucity of high-quality randomised evidence on long-established treatment options (SPS and CPS) and a limited evidence base for hyperkalaemia management with these agents.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29381246     DOI: 10.1111/ijcp.13052

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

Review 1.  Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.

Authors:  Redi Llubani; Davor Vukadinović; Christian Werner; Nikolaus Marx; Stephen Zewinger; Michael Böhm
Journal:  Curr Heart Fail Rep       Date:  2018-12

2.  Polysulfonate Resins in Hyperkalemia: A Systematic Review.

Authors:  Sheung Wing Sherwin Wong; Grace Zhang; Patrick Norman; Hasitha Welihinda; Don Thiwanka Wijeratne
Journal:  Can J Kidney Health Dis       Date:  2020-10-30

3.  Initial and Recurrent Hyperkalemia Events in Patients With CKD in Older Adults: A Population-Based Cohort Study.

Authors:  Sriram Sriperumbuduri; Eric McArthur; Gregory L Hundemer; Mark Canney; Navdeep Tangri; Silvia J Leon; Sara Bota; Ann Bugeja; Ayub Akbari; Greg Knoll; Manish M Sood
Journal:  Can J Kidney Health Dis       Date:  2021-05-27

4.  Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Marinella Ruospo; Valeria M Saglimbene; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2020-06-26

5.  Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review.

Authors:  Fabiana R Varallo; Victória Trombotto; Rosa C Lucchetta; Patricia de C Mastroianni
Journal:  Pharm Pract (Granada)       Date:  2019-03-04

6.  Calcium salt administration for circulatory shock due to severe hyperkalemia.

Authors:  Zohair Al Aseri
Journal:  Saudi J Anaesth       Date:  2019 Jul-Sep
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.